 |
Sept. 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read
Aug. 5, 2021 - Puma Biotechnology Reports Second Quarter 2021 Financial Results
Read
July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
Read
July 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 15, 2021 - NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.
Read
July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
Read
June 4, 2021 - Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Read
June 4, 2021 - Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Read
June 4, 2021 - Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
Read
May 19, 2021 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
Read
May 6, 2021 - Puma Biotechnology Reports First Quarter 2021 Financial Results
Read
April 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read
March 4, 2021 - Puma Biotechnology to Present at the Barclays Global Healthcare Conference
Read
March 2, 2021 - Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference
Read
February 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
Read
February 25, 2021 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
February 11, 2021 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Read
January 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
Read
January 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference
Read
January 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI
Read
January 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Read
January 4, 2021 - Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
Read
|
|
Upcoming Events
Sept. 7, 2021 - H.C. Wainwright 23rd Annual Global Investment Conference
More
Past Events
Aug. 5, 2021 - Puma Biotechnology 2Q-2021 Financial Results Conference Call
More
June 4-8, 2021 - ASCO 2021 Annual Meeting
More
May 6, 2021 - Puma Biotechnology 1Q-2021 Financial Results Conference Call
More
Mar. 11, 2021 - Barclays Global Healthcare Conference
More
Mar. 9, 2021 - H.C. Wainwright Global Life Sciences Conference
More
Mar. 2, 2021 - Cowen and Company 41st Annual Health Care Conference
More
Feb. 25, 2021 - Puma Biotechnology 4Q-2020 Financial Results Conference Call
More
Jan. 26-29, 2021 - IASLC 2021 World Conference on Lung Cancers
More
Jan. 21, 2021 - B. Riley Oncology Investor Conference
More
Jan. 15-17, 2021 - ASCO 2021 Gastrointestinal Cancers Symposium
More
Jan. 14, 2021 - 39th Annual J.P. Morgan Healthcare Conference
More
Jan. 11, 2021 - H.C. Wainwright VIRTUAL BioConnect Conference
More
|
Annual Report Archives
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com
Business Development:
info@pumabiotechnology.com
Investor Relations:
ir@pumabiotechnology.com
Follow Us:
|
